A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Official title

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Study identification

NCT ID

NCT05675410

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 3

Lead sponsor

National Cancer Institute (NCI)

NIH

Enrollment

1,875 participants

Conditions and interventions

Eligibility (public fields only)

Age range

5 Years to 60 Years

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

May 10, 2023

Primary completion

Apr 27, 2031

Completion

Apr 27, 2031

Last update posted

May 6, 2026

2023 – 2031

United States locations

U.S. sites

389

U.S. states

49

U.S. cities

292

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.